CareDx logo

CareDxNASDAQ: CDNA

Profile

Sector:

Healthcare

Country:

United States

IPO:

17 July 2014

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$1.21 B
-52%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
-34%vs. 3y high
80%vs. sector
-55%vs. 3y high
55%vs. sector

Price

after hours | Mon, 04 Nov 2024 22:20:15 GMT
$23.00$0.00(0.00%)

Dividend

No data over the past 3 years
$92.27 M$80.53 M
$92.27 M-$1.39 M

Analysts recommendations

Institutional Ownership

CDNA Latest News

CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
seekingalpha.com04 November 2024 Sentiment: -

CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
accesswire.com25 October 2024 Sentiment: NEGATIVE

NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
prnewswire.com11 October 2024 Sentiment: NEGATIVE

NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com11 October 2024 Sentiment: POSITIVE

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company's newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
accesswire.com30 September 2024 Sentiment: NEGATIVE

NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
seekingalpha.com29 September 2024 Sentiment: POSITIVE

CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives.

SHAREHOLDER ALERT: Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc.; Shareholders are Encouraged to Contact the Firm
globenewswire.com24 September 2024 Sentiment: NEGATIVE

Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund.

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com13 September 2024 Sentiment: POSITIVE

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx's common stock (the “Kennedy Inducement Option”) and 70,101 restricted stock units (the “Kennedy Indu.

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com13 September 2024 Sentiment: POSITIVE

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares o.

CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
zacks.com09 August 2024 Sentiment: POSITIVE

CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • 1(current)

What type of business is CareDx?

CareDx, Inc. is a leading precision medicine company focused on discovering, developing, and commercializing clinically differentiated, high-value medical solutions for transplant patients and caregivers. CareDx, Inc. was founded in 1998 and is headquartered in South San Francisco, California. The company also develops, manufactures, and markets products that increase the likelihood of successful transplantation by facilitating matching between donor and recipient stem cells and organs. Key products of CareDx, Inc. include: - AlloSure Kidney - a cell-free DNA obtained from the donor (dd-cfDNA) solution for kidney transplant patients - AlloMap Heart - a gene expression solution for patients who have undergone heart transplantation.

What sector is CareDx in?

CareDx is in the Healthcare sector

What industry is CareDx in?

CareDx is in the Diagnostics & Research industry

What country is CareDx from?

CareDx is headquartered in United States

When did CareDx go public?

CareDx initial public offering (IPO) was on 17 July 2014

What is CareDx website?

https://caredx.com

Is CareDx in the S&P 500?

No, CareDx is not included in the S&P 500 index

Is CareDx in the NASDAQ 100?

No, CareDx is not included in the NASDAQ 100 index

Is CareDx in the Dow Jones?

No, CareDx is not included in the Dow Jones index

When was CareDx the previous earnings report?

No data

When does CareDx earnings report?

Next earnings report date is not announced yet